Beeswax venom (BWV) formulation is composed of bee wax (BW) (98.29) and bee venom (BV) (1.71%) possesses various medicinally important molecule lead us to elucidate its antidiabetic property in high-fat diet (HFD) and low dose streptozotocin (STZ) induced type 2 diabetic rats.
Type 2 diabetes mellitus (T2DM) was induced by feeding HFD for 2 weeks followed by the injection of single dose of 35 mg/kg STZ. After 3 weeks of oral administration of BWV formulation (0.125, 0.250 and 0.500 mg/kg) and metformin (MET) 180mg/kg, the biochemical parameters such as serum glucose, serum insulin, lipid profile, liver marker enzymes was estimated. Furthermore, western blot analysis of liver peroxisome proliferator activated receptor-γ (PPAR-γ), CCAAT/enhancer binding protein (C/EBP- β) and CCAAT/enhancer binding protein-alpha (C/EBP-α) was performed. Histological analysis of pancreas was also studied.
Oral administration of BWV formulation (0.125, 0.250 and 0.500 mg/kg) and metformin 180mg/kg significantly reduced the levels of serum glucose, total cholesterol (TC), triglycerides (TG), liver marker enzyme and significantly increased the serum insulin and body weight. Furthermore, BWV formulation treatment enhanced the liver PPAR-γ, C/EBP- β and C/EBP-α protein expression. At the same time histological analysis of pancreas showed significant amelioration of β-cell damage.
Our results suggest that BWV formulation regulated the abnormalities of glucose and lipid metabolism by its PPAR-γ agonist property in HFD low dose induced type 2 diabetic rats.